查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2008756

灰指甲治疗市场报告：按疾病类型、治疗类型、药物类别、分销管道和地区划分，2026-2034 年

Onychomycosis Treatment Market Report by Disease Type, Treatment Type, Drug Class, Distribution Channel, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 147 Pages | 商品交期: 2-3个工作天内

价格

2025年，全球灰指甲治疗市场规模达38亿美元。展望未来，IMARC集团预测，该市场将在2026年至2034年间以4.15%的复合年增长率成长，到2034年达到55亿美元。北美凭藉其完善的医疗保健基础设施，在该市场中展现出明显的优势。成人和千禧世代中这种真菌感染的日益普遍，是成长要素的主要因素，而这又受到公共感染疾病使用增多以及穿着紧身衣物、受污染衣物或脏鞋袜等因素的影响。

市场规模及预测：

  • 2025年，灰指甲治疗市场价值将达到38亿美元。
  • 预计从 2026 年到 2034 年，该产业将以 4.15% 的复合年增长率成长，到 2034 年达到 55 亿美元。

主要部分：

  • 疾病类型：目前，远端甲下真菌病在市场上占据主导地位。此病以甲床和甲板下侧感染为特征，导致指甲变色、增厚和脱落。
  • 治疗方法：药物治疗，包括口服和外用抗真菌药物，占据了最大的市场份额，并且每种药物都已证明对治疗这种疾病有明显的疗效。
  • 分销管道：零售药局占据了大部分市场份额，这反映了它们在抗真菌药物的分销和供应方面发挥的关键作用。
  • 地区：北美市场领先，这得益于外用指甲油和药膏在保持指甲卫生方面的使用日益增多。

主要企业：

  • 市场上的主要企业包括博士伦健康公司、西普拉有限公司、瑞迪博士实验室有限公司、高德美控股公司、葛兰素史克公司、嘉健製药株式会社、Lumenis Be Ltd、Moberg Pharma AB (publ)、诺华公司、辉瑞公司、TheOTCLab BV 和西安杨森製药有限公司。

市场成长的主要驱动因素：

  • 灰指甲的盛行率不断上升：不同年龄层中灰指甲病例的增加，以及糖尿病和其他健康状况的出现，推动了对有效治疗方法的需求。
  • 治疗方法创新：持续的研究和创新催生了新的抗真菌治疗方法，包括口服药物、外用药物和雷射疗法，从而提高了治疗效率和患者疗效。
  • 认知水平和诊断能力的提高：人们对灰指甲的认识不断提高，诊断技术的进步使得早期诊断和治疗成为可能，从而促进了市场扩张。治疗可近性的提高：非处方药的普及和专科诊所的增加，使更多患者更容易获得治疗。
  • 人们对美观的关注度日益提高：与指甲外观相关的问题越来越多，促使人们寻求治疗，尤其是在美容和美学机构。这推动了市场成长。

未来展望：

  • 强劲的成长前景：在持续创新、意识提高和治疗方法可近性扩大的推动下，灰指甲治疗市场可望长期成长。
  • 市场演变：该行业正朝着根据每位患者的具体情况量身定制的个人化治疗方向发展，最终目标是为灰指甲提供更有效、更有针对性的治疗。

随着全球医疗保健格局的演变，灰指甲治疗市场正经历着强劲的成长和转型，这反映出感染疾病的不断上升。法规环境灰指甲食品药物管理局核准确保治疗方法的安全性和有效性，这增强了患者对现有治疗方法的信心，并促进了新治疗方法的应用。

灰指甲治疗市场趋势：

治疗技术方面的技术进步

治疗技术的进步对灰指甲治疗领域产生了重大影响。持续的研发推动了新型抗真菌药物、雷射疗法和更先进的诊断方法的发展。口服抗真菌药物，如Terbinafine和Itraconazole，正在不断改进以提高疗效，而外用药物也在不断发展，以提供更便捷、更无痛的治疗选择。雷射疗法利用高能量光杀灭真菌感染疾病，因其高精度和低副作用而日益普及。此外，能够更准确、更快速地识别病原体的新型诊断技术，使得早期治疗和改善治疗效果成为可能。这些进步使治疗更安全、更有效、更方便。因此，随着新技术不断改善整体治疗体验，灰指甲治疗市场持续成长。 2024年，Eisai宣布与佐藤製药株式会社就抗真菌药物福沙康唑在亚太地区的开发和商业化权利达成许可协议。根据该协议，Eisai将授予佐藤製药在指定国家和地区福沙康唑智慧财产权的独家使用权。

对灰指甲的认识提高

人们对灰指甲）的认识不断提高，是推动治疗市场发展的主要动力。各方正加强提高大众对感染疾病原因、症状及相关风险的认识。医疗机构、皮肤科医生和公共卫生组织正在广泛传播灰指甲的治疗方法和预防讯息。因此，人们对这种疾病的认识不断提高，越来越多的人开始寻求早期治疗。在以往因感染疾病而遭受歧视、不愿就医的地区，这种情况尤其明显。随着资讯获取管道的增多，患者开始更加关注自身健康，从而增加了对诊断和治疗的需求。这种认知的提升正在打造一个更了解相关知识的患者群体，推动市场扩张，因为人们都在寻求能够改善生活品质的解决方案。 2024年，美国疾病管制与预防中心（CDC）和世界卫生组织（WHO）共同举办了“2024年真菌感染疾病宣传週”，专家们在活动中共用了诊断方法和药敏试验方面的资讯。这些努力也提高了人们对灰指甲等真菌感染疾病的认识。

人口老化与人口结构变化

老年人口的成长在扩大市场规模方面发挥着重要作用。根据世界卫生组织预测，2030年，60岁及以上人口预计将增加14亿人。随着老龄化，免疫力往往会下降，血液循环也会减慢，这两者都会增加灰指甲）的风险。此外，老年人通常还患有糖尿病和周边血管疾病等合併症，进一步增加了患病风险。人口老化趋势，尤其是在已开发国家，使得针对老年族群的治疗需求日益增长。製药公司正致力于开发安全有效的老年患者治疗方法，因为老年患者通常对某些药物有禁忌症或过敏反应。因此，市场对适合老年人的治疗方法的需求不断增长，包括副作用小、使用方便的治疗方法（例如，局部抗真菌药物和雷射治疗）。

灰指甲治疗市场成长要素：

灰指甲）发生率增加

灰指甲盛行率的不断上升正在推动市场成长。随着全球人口老化，感染疾病的发生率不断上升，尤其是在老年族群中。老年人容易出现血液循环不良、免疫力下降、指甲结构改变等问题，这些都会增加罹患灰指甲的风险。此外，随着糖尿病等慢性疾病盛行率的增加，甲癣的风险也持续上升。随着越来越多的人患上灰指甲，对该疾病的感染疾病需求也增加。医疗专业人员积极主动的早期诊断和治疗也促进了治疗率的提高。因此，皮肤科医生和製药公司正致力于为这些患者群体开发新的、更有效的治疗方法。

人们越来越倾向于非侵入性治疗

人们对非侵入性治疗的日益青睐正在改变灰指甲）的治疗市场。患者正在寻求口服药物的替代方案，因为口服药物可能有副作用且需要长期治疗。外用抗真菌凝胶和指甲油因其使用方便且无需处方即可购买而越来越受欢迎。与口服药物相比，这些药物被认为风险较低、使用更便捷。此外，雷射疗法等非手术治疗方法在临床实践中也越来越受欢迎，因为它们无需药物即可治癒感染，且恢復时间短。对于那些担心口服抗真菌药物副作用和全身性影响的患者来说，非侵入性治疗尤其具有吸引力。

扩大治疗途径

扩大灰指甲治疗的可近性是成长要素之一。随着全球医疗保健体系的改善，患者，尤其是在偏远和医疗资源匮乏地区的患者，更容易获得治疗选择。非处方抗真菌药物的日益普及是扩大治疗可近性的主要因素。对于轻度灰指甲患者，不再需要处方笺，这使得治疗更加便利且费用更低。线上药局和电子商务网站的兴起，让消费者足不出户即可购买药物，提高了药局和医疗设施匮乏地区的用药便利性。此外，专科皮肤科诊所的增加也改善了患者获得专业护理的机会，使他们能够获得最适合自身病情的治疗。这些不断增加的治疗机会正促使更多人寻求治疗。

目录

第一章：序言

第二章：调查方法

  • 调查目的
  • 相关利益者
  • 数据来源
    • 主要讯息
    • 次要讯息
  • 市场估值
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章执行摘要

第四章：引言

第五章：全球灰指甲治疗市场

  • 市场概览
  • 市场表现
  • 新冠疫情的影响
  • 市场预测

第六章 市场区隔：依疾病类型划分

  • 远端甲下真菌病
  • 近端甲下真菌病
  • 白色表灰指甲
  • 念珠菌灰指甲
  • 其他的

第七章 市场区隔：依治疗类型划分

  • 雷射疗法
  • 动态疗法
  • 药物治疗

第八章 市场区隔：依药物类别划分

  • Allylamines系列
  • Azole
  • 灰黄霉素
  • 其他的

第九章 市场区隔：依分销通路划分

  • 医院和诊所
  • 网路商店
  • 零售药房
  • 其他的

第十章 市场区隔：依地区划分

  • 北美洲
    • 我们
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第十一章 SWOT 分析

第十二章：价值链分析

第十三章：波特五力分析

第十四章：价格分析

第十五章 竞争格局

  • 市场结构
  • 主要企业
  • 主要企业简介
    • Bausch Health Companies Inc.
    • Cipla Limited
    • Dr. Reddy's Laboratories Ltd.
    • Galderma Holding SA
    • GSK plc.
    • Kaken Pharmaceutical Co., Ltd.
    • Lumenis Be Ltd
    • Moberg Pharma AB（publ）
    • Novartis AG
    • Pfizer Inc.
    • TheOTCLab BV
    • Xian Janssen Pharmaceutical Ltd.
Product Code: SR112026A4877

The global onychomycosis treatment market size reached USD 3.8 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 5.5 Billion by 2034, exhibiting a growth rate (CAGR) of 4.15% during 2026-2034. North America exhibits a clear dominance in the market, owing to the improvements in the healthcare infrastructure. The rising prevalence of this fungal infection among adults and millennials due to the increased exposure to public swimming pools and the use of tight, contaminated, or soiled clothes, shoes, socks, etc., is primarily driving the market.

MARKET SIZE & FORECASTS:

  • Onychomycosis treatment market was valued at USD 3.8 Billion in 2025.
  • The market is projected to reach USD 5.5 Billion by 2034, at a CAGR of 4.15% from 2026-2034.

DOMINANT SEGMENTS:

  • Disease Type: Distal subungual onychomycosis currently exhibits a clear dominance in the market, characterized by the invasion of the nail bed and underside of the nail plate, leading to discoloration, thickening, and detachment of the nail.
  • Treatment Type: Drug treatment holds the biggest market share as it involves oral and topical antifungal medications, each with distinct examples of efficacy in treating the condition.
  • Distribution Channel: Retail pharmacies account for the majority of the total market share, reflecting their pivotal role in the distribution and accessibility of antifungal medications.
  • Region: North America leads the market, owing to the elevating usage of topical nail lacquers and ointments to maintain nail hygiene.

KEY PLAYERS:

  • The leading companies in the market include Bausch Health Companies Inc., Cipla Limited, Dr. Reddy's Laboratories Ltd., Galderma Holding S.A., GSK plc., Kaken Pharmaceutical Co., Ltd., Lumenis Be Ltd, Moberg Pharma AB (publ), Novartis AG, Pfizer Inc., TheOTCLab B.V., Xian Janssen Pharmaceutical Ltd., etc.

KEY DRIVERS OF MARKET GROWTH:

  • Growth in Onychomycosis Prevalence: Increased cases of onychomycosis, spurred by age groups, diabetes, and other health ailments, are driving demand for successful treatments.
  • Innovation in Treatment: Continued research and innovation are bringing emerging antifungal treatments, such as oral drugs, topical medications, and laser treatments, which enhance treatment efficiency and patient outcomes.
  • Rising Awareness and Diagnosis Levels: Greater awareness about onychomycosis and improved diagnostics are causing earlier diagnosis and treatment, thus opening up the market. Better Accessibility to Treatment: The increasing availability of over-the-counter treatment and more specialized clinics are increasing the accessibility to treatment to a larger patient base.
  • Increasing Aesthetic Issues: Increasing issues related to the look of nails are leading people to opt for treatment, especially in cosmetic and aesthetic settings, which is fueling the growth of the market.

FUTURE OUTLOOK:

  • Strong Growth Outlook: The market for the treatment of onychomycosis is witnessing prolonged growth, driven by ongoing innovation, heightened awareness, and wider accessibility to treatment modalities.
  • Market Evolution: The industry is shifting in favor of personalized therapies that are specific to the patient's profile, with the end goal of bringing more efficient and targeted treatments to onychomycosis.

Onychomycosis treatment market is witnessing strong growth and change as the world's healthcare dynamics evolve to reflect the increased incidence of fungal nail infections. Currently, the regulatory environment is in the process of change as governments and healthcare agencies across the globe are recognizing the increasing burden of onychomycosis. Organizations like the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) are also rapidly approving new antifungal therapies, driving additional innovation in the industry. Moreover, regulatory agencies are striving to make treatments safe and effective, which is contributing toward the trust of patients in existing treatments and toward more widespread use of new therapy.

ONYCHOMYCOSIS TREATMENT MARKET TRENDS:

Technological Advances in Treatment Techniques

Technological progresses in treatment techniques are having a strong influence on the onychomycosis treatment sector. Ongoing research and development (R&D) are fueling new antifungal drugs, laser therapy, and more sophisticated diagnostics. Oral antifungal drugs like terbinafine and itraconazole are being improved to increase their efficacy, while topical drugs are adapting to provide more accessible and less painful alternatives. Laser therapy, which focuses light energy to kill fungal infections, is becoming increasingly popular because it provides precise and limited side effects. In addition, novel diagnostic technologies that facilitate more precise and quicker identification are improving treatment outcomes by enabling earlier treatment. Such advances are making treatments safer, more effective, and more convenient for patients to receive. Consequently, the onychomycosis treatment market is growing as new technology improves the overall experience of treatment. In 2024, Eisai Company, Limited declared that the company signed a licensing agreement concerning the development and commercialization rights for the antifungal drug fosravuconazole in the Asia/Oceania region* with Sato Pharmaceutical Co., Ltd. Under this agreement, Eisai grants Sato Pharma exclusive rights to the intellectual property of fosravuconazole in the specified countries/regions.

Increased Awareness about Onychomycosis

Increased awareness about onychomycosis is a major driver for the treatment market. Rising efforts to make the population aware of the cause, symptoms, and risks associated with fungal nail infections are witnessing. Health institutions, dermatologists, and public health initiatives are disseminating information on how treatment and prevention of onychomycosis can be achieved. Consequently, more people are becoming aware of the condition and going for early treatment. This is particularly relevant in areas where the stigma attached to nail infections has previously made people reluctant to go for medical care. As information becomes more readily available, patients are increasingly taking control of the problem, resulting in increased diagnosis and treatment demand. The heightened awareness is building a more educated patient base, which is driving market expansion as people seek solutions to enhance their quality of life. In 2024, CDC and WHO conducted Fungal Disease Awareness Week 2024, where experts shared information in diagnostics and susceptibility testing. These initiatives were also responsible for increasing the awareness about fungal diseases like onychomycosis.

Aging Population and Demographic Changes

The growing population of older individuals is playing a big role in the expansion of the market size. According to the predictions of WHO, the number of individuals aged 60 and over will increase 1.4 billion by 2030. As individuals grow older, immune systems are weakened, and circulation tends to decrease, both of which heighten the risk of fungal nail infections. In addition, older persons tend to have more comorbid conditions like diabetes or peripheral vascular disease, further increasing their risk. The shift in demographics to an aging population, specifically within developed areas, is driving the need for treatments specific to this population. Pharmaceutical organizations are emphasizing developing therapy that is safe and effective for the elderly patient, many of whom will have contraindications or sensitivities to certain drugs. Thus, the market is observing a rise in demand for treatments that are appropriate for the aging population, including those with minimal side effects and simpler administration techniques, for example, topical antifungal solutions or laser treatments.

ONYCHOMYCOSIS TREATMENT MARKET GROWTH DRIVERS:

Growing Incidence of Onychomycosis

The increasing prevalence of onychomycosis is impelling the market growth. With an aging global population, the rates of fungal nail infection are rising, especially in older adults. Such individuals tend to have compromised blood circulation, weakened immune systems, and altered nail structure, all of which predispose them to onychomycosis. Also, with increasing prevalence of chronic diseases like diabetes, the risk of fungal infection of the nails continues to rise. With more individuals suffering from onychomycosis, there has been a growing need for treatment of the condition. Healthcare professionals are more actively diagnosing and treating the condition early, which is part of the reasons for increasing treatment rates. Consequently, dermatologists and pharmaceutical firms are concentrating on creating new and better treatments for these section of patients.

Growing Preference for Non-Invasive Treatments

The growing preference for non-invasive treatments is transforming the market for onychomycosis treatment. Patients are looking for alternatives to oral drugs, which can have side effects or cause extended treatment regimens. Topical medications, like antifungal gels and lacquers, are increasingly popular since they are convenient to use and may be purchased over the counter. These medications are viewed as less risky and more convenient than oral drugs. In addition, non-surgical methods such as laser treatment are also gaining popularity within the clinic because they can cure the infection without drugs and with minimal recovery time. Non-invasive treatments are especially attractive to patients who are worried about the possible side effects or systemic effects of oral antifungal therapy.

Increasing Access to Treatment

Increasing access to onychomycosis treatment is one of the drivers of the market. With improving healthcare systems around the world, treatment options are readily available to patients, especially in remote or underprivileged regions. The growing availability of antifungal medication over the counter is a major aspect of how access is becoming greater. Patients no longer require a prescription for less severe cases of onychomycosis, making treatment easier and less expensive. Also, the rise of online pharmacies and e-commerce sites is giving customers the option to buy medicines from the convenience of their homes, enhancing the accessibility of medication in areas where there are limited pharmacies or healthcare centers. Moreover, the increase in number of specialist dermatology clinics is enhancing access to expert care so that patients are provided with the most suitable treatment for their ailment. This increased availability is driving more individuals to pursue care.

GLOBAL ONYCHOMYCOSIS TREATMENT INDUSTRY SEGMENTATION:

Breakup by Disease Type:

  • Distal Subungual Onychomycosis
  • Proximal Subungual Onychomycosis
  • White Superficial Onychomycosis
  • Candidal Onychomycosis
  • Others

Distal subungual onychomycosis currently exhibits a clear dominance in the market

Distal subungual onychomycosis (DSO) is the most common form of fungal nail infection, characterized by the invasion of the nail bed and underside of the nail plate, leading to discoloration, thickening, and detachment of the nail. Recent advancements in the treatment of DSO have seen the launch of several innovative therapies aimed at improving patient outcomes. Topical antifungal solutions with enhanced nail penetration capabilities, such as efinaconazole and tavaborole, have been introduced, providing effective alternatives to oral medications. Additionally, the advent of laser treatments specifically designed for DSO has gained traction, offering a non-invasive and painless option that targets the fungal pathogens directly. New combination therapies, integrating both topical and oral agents, have also been launched to tackle the persistent nature of DSO by employing a multifaceted approach. In November 2023, Blueberry Therapeutics Limited, one of the pharmaceutical companies focused on developing innovative nanomedicines to treat dermatological conditions, introduced BB2603, a novel topical terbinafine antifungal product to treat distal subungual onychomycosis.

Breakup by Treatment Type:

  • Laser Therapy
  • Photodynamic Therapy
  • Drug Treatment

Currently, drug treatment holds the largest market share

Drug treatment for onychomycosis mainly involves oral and topical antifungal medications, each with distinct examples of efficacy in treating the condition. Oral antifungals like terbinafine (Lamisil) and itraconazole are commonly prescribed due to their ability to reach the nail bed through the bloodstream, effectively targeting the fungal infection from within. On the other hand, topical treatments, such as ciclopirox and efinaconazole, offer non-invasive options that are applied directly to the affected nail. Ciclopirox is a nail lacquer that is applied daily and gradually penetrates the nail to eradicate the fungus. For example, in July 2022, Zydus Lifesciences received approval from the U.S. Food and Drug Administration (USFDA) to market an antifungal efinaconazole topical solution for onychomycosis.

Breakup by Drug Class:

  • Allylamine
  • Azole
  • Griseofulvin
  • Others

Allylamines, such as terbinafine, are prominently featured due to their high efficacy and relatively short treatment duration, making them a preferred choice for both patients and healthcare providers. Azoles, including itraconazole and fluconazole, are also thoroughly examined, highlighting their broad-spectrum antifungal activity and flexibility in dosing regimens, which cater to patients requiring alternative treatment options. Griseofulvin, an older antifungal, is analyzed for its continued use in cases where other treatments are contraindicated. The report further explores other emerging drug classes and novel antifungal agents that are being developed to address the limitations of existing therapies, which is propelling the onychomycosis treatment market share. This analysis not only informs about the market dynamics but also aids in understanding the evolving preferences and trends in antifungal treatments.

Breakup by Distribution Channel:

  • Hospitals and Clinics
  • Online Stores
  • Retail Pharmacies
  • Others

Retail pharmacies account for the majority of the total market share

Retail pharmacies represented the largest segment in the onychomycosis treatment market, reflecting their pivotal role in the distribution and accessibility of antifungal medications. This dominance is attributed to the convenience and widespread availability of retail pharmacies, making it easier for patients to obtain both prescription and over-the-counter treatments. For example, widely used oral antifungals like terbinafine (Lamisil) and itraconazole (Sporanox) are commonly dispensed through retail pharmacies, allowing for prompt initiation of treatment following a diagnosis. Additionally, popular, topical solutions such as ciclopirox (Penlac) and efinaconazole (Jublia) are readily accessible at these outlets, providing non-invasive treatment options for patients. The extensive reach of retail pharmacies, often supplemented by in-store pharmacist consultations, supports patient adherence to treatment regimens, thereby enhancing the effectiveness of therapy. This segment's growth is further bolstered by the increasing availability of online pharmacy services, which offer added convenience and discreet purchasing options, catering to the evolving preferences of consumers seeking onychomycosis treatments.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America currently dominates the market

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

The expanding geriatric population is primarily driving the market. The Census Bureau estimated that more than 55 million individuals in the U.S. are aged 65 years or older, out of which one-fourth live in one of three states, namely Florida, California, and Texas. Besides this, the rising number of regulatory approvals is also acting as another significant growth-inducing factor. For example, in April 2021, Alembic Pharmaceuticals Limited (Alembic) announced that its joint venture Aleor Dermaceuticals Limited (Aleor) received tentative approval from the U.S. Food & Drug Administration (US FDA) for its abbreviated new drug application (ANDA) for the treatment of onychomycosis in the toenail. Similarly, in February 2021, Lupin Limited received the U.S. Food and Drug Administration's approval for its tavaborole topical solution for onychomycosis.

Competitive Landscape:

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major market companies have also been provided. Some of the key players in the market include:

  • Bausch Health Companies Inc.
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Galderma Holding S.A.
  • GSK plc.
  • Kaken Pharmaceutical Co., Ltd.
  • Lumenis Be Ltd
  • Moberg Pharma AB (publ)
  • Novartis AG
  • Pfizer Inc.
  • TheOTCLab B.V.
  • Xian Janssen Pharmaceutical Ltd.

KEY QUESTIONS ANSWERED IN THIS REPORT

1. What was the size of the global onychomycosis treatment market in 2025?

2. What is the expected growth rate of the global onychomycosis treatment market during 2026-2034?

3. What are the key factors driving the global onychomycosis treatment market?

4. What has been the impact of COVID-19 on the global onychomycosis treatment market?

5. What is the breakup of the global onychomycosis treatment market based on the disease type?

6. What is the breakup of the global onychomycosis treatment market based on the treatment type?

7. What is the breakup of the global onychomycosis treatment market based on the distribution channel?

8. What are the key regions in the global onychomycosis treatment market?

9. Who are the key players/companies in the global onychomycosis treatment market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Onychomycosis Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Disease Type

  • 6.1 Distal Subungual Onychomycosis
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Proximal Subungual Onychomycosis
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 White Superficial Onychomycosis
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Candidal Onychomycosis
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Treatment Type

  • 7.1 Laser Therapy
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Photodynamic Therapy
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Drug Treatment
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Drug Class

  • 8.1 Allylamine
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Azole
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Griseofulvin
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Hospitals and Clinics
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Online Stores
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Retail Pharmacies
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Others
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Bausch Health Companies Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Cipla Limited
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
    • 15.3.3 Dr. Reddy's Laboratories Ltd.
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Galderma Holding S.A.
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
    • 15.3.5 GSK plc.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Kaken Pharmaceutical Co., Ltd.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
    • 15.3.7 Lumenis Be Ltd
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 SWOT Analysis
    • 15.3.8 Moberg Pharma AB (publ)
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
    • 15.3.9 Novartis AG
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Pfizer Inc.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 TheOTCLab B.V.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
    • 15.3.12 Xian Janssen Pharmaceutical Ltd.
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Onychomycosis Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Onychomycosis Treatment Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Onychomycosis Treatment Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Onychomycosis Treatment Market: Breakup by Disease Type (in %), 2025
  • Figure 5: Global: Onychomycosis Treatment Market: Breakup by Treatment Type (in %), 2025
  • Figure 6: Global: Onychomycosis Treatment Market: Breakup by Drug Class (in %), 2025
  • Figure 7: Global: Onychomycosis Treatment Market: Breakup by Distribution Channel (in %), 2025
  • Figure 8: Global: Onychomycosis Treatment Market: Breakup by Region (in %), 2025
  • Figure 9: Global: Onychomycosis Treatment (Distal Subungual Onychomycosis) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 10: Global: Onychomycosis Treatment (Distal Subungual Onychomycosis) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 11: Global: Onychomycosis Treatment (Proximal Subungual Onychomycosis) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Onychomycosis Treatment (Proximal Subungual Onychomycosis) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Onychomycosis Treatment (White Superficial Onychomycosis) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Onychomycosis Treatment (White Superficial Onychomycosis) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: Onychomycosis Treatment (Candidal Onychomycosis) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: Onychomycosis Treatment (Candidal Onychomycosis) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: Onychomycosis Treatment (Other Disease Types) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: Onychomycosis Treatment (Other Disease Types) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: Onychomycosis Treatment (Laser Therapy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: Onychomycosis Treatment (Laser Therapy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: Global: Onychomycosis Treatment (Photodynamic Therapy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: Global: Onychomycosis Treatment (Photodynamic Therapy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: Global: Onychomycosis Treatment (Drug Treatment) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: Global: Onychomycosis Treatment (Drug Treatment) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: Global: Onychomycosis Treatment (Allylamine) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: Global: Onychomycosis Treatment (Allylamine) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: Global: Onychomycosis Treatment (Azole) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: Global: Onychomycosis Treatment (Azole) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: Global: Onychomycosis Treatment (Griseofulvin) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: Global: Onychomycosis Treatment (Griseofulvin) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: Global: Onychomycosis Treatment (Other Drug Classes) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: Global: Onychomycosis Treatment (Other Drug Classes) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: Global: Onychomycosis Treatment (Hospitals and Clinics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: Global: Onychomycosis Treatment (Hospitals and Clinics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: Global: Onychomycosis Treatment (Online Stores) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: Global: Onychomycosis Treatment (Online Stores) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: Global: Onychomycosis Treatment (Retail Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: Global: Onychomycosis Treatment (Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: Global: Onychomycosis Treatment (Other Distribution Channels) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: Global: Onychomycosis Treatment (Other Distribution Channels) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: North America: Onychomycosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: North America: Onychomycosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: United States: Onychomycosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: United States: Onychomycosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: Canada: Onychomycosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: Canada: Onychomycosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: Asia-Pacific: Onychomycosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 48: Asia-Pacific: Onychomycosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 49: China: Onychomycosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 50: China: Onychomycosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 51: Japan: Onychomycosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 52: Japan: Onychomycosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 53: India: Onychomycosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: India: Onychomycosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: South Korea: Onychomycosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: South Korea: Onychomycosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: Australia: Onychomycosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: Australia: Onychomycosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: Indonesia: Onychomycosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: Indonesia: Onychomycosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: Others: Onychomycosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: Others: Onychomycosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: Europe: Onychomycosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 64: Europe: Onychomycosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 65: Germany: Onychomycosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 66: Germany: Onychomycosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 67: France: Onychomycosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 68: France: Onychomycosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 69: United Kingdom: Onychomycosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 70: United Kingdom: Onychomycosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 71: Italy: Onychomycosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 72: Italy: Onychomycosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 73: Spain: Onychomycosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 74: Spain: Onychomycosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 75: Russia: Onychomycosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 76: Russia: Onychomycosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 77: Others: Onychomycosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 78: Others: Onychomycosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 79: Latin America: Onychomycosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 80: Latin America: Onychomycosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 81: Brazil: Onychomycosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 82: Brazil: Onychomycosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 83: Mexico: Onychomycosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 84: Mexico: Onychomycosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 85: Others: Onychomycosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 86: Others: Onychomycosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 87: Middle East and Africa: Onychomycosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 88: Middle East and Africa: Onychomycosis Treatment Market: Breakup by Country (in %), 2025
  • Figure 89: Middle East and Africa: Onychomycosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 90: Global: Onychomycosis Treatment Industry: SWOT Analysis
  • Figure 91: Global: Onychomycosis Treatment Industry: Value Chain Analysis
  • Figure 92: Global: Onychomycosis Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Onychomycosis Treatment Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Onychomycosis Treatment Market Forecast: Breakup by Disease Type (in Million USD), 2026-2034
  • Table 3: Global: Onychomycosis Treatment Market Forecast: Breakup by Treatment Type (in Million USD), 2026-2034
  • Table 4: Global: Onychomycosis Treatment Market Forecast: Breakup by Drug Class (in Million USD), 2026-2034
  • Table 5: Global: Onychomycosis Treatment Market Forecast: Breakup by Distribution Channel (in Million USD), 2026-2034
  • Table 6: Global: Onychomycosis Treatment Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 7: Global: Onychomycosis Treatment Market: Competitive Structure
  • Table 8: Global: Onychomycosis Treatment Market: Key Players